Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

PhaseBio Pharmaceuticals, Inc. (PHAS)

0.0701   0 (0%) 11-02 16:00
Open: 0.0807 Pre. Close: 0.0701
High: 0.092 Low: 0.0665
Volume: 8,603,716 Market Cap: 3(M)

Technical analysis

as of: 2023-01-06 4:33:43 PM
Overall:       
Stoxline posted a NEUTRAL today, same as yesterday. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Target: Six months: 0.11     One year: 0.16
Support: Support1: 0.04    Support2: 0.03
Resistance: Resistance1: 0.1    Resistance2: 0.13
Pivot: 0.05
Moving Average: MA(5): 0.04     MA(20): 0.06
MA(100): 0.59     MA(250): 1.03
MACD: MACD(12,26): -0.1     Signal(9): -0.1
Stochastic oscillator: %K(14,3): 5.1     %D(3): 4.5
RSI: RSI(14): 32
52-week: High: 2.7  Low: 0.04
Average Vol(K): 3-Month: 2,069 (K)  10-Days: 369 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ PHAS ] has closed above bottom band by 38.0%. Bollinger Bands are 75.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 37 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 0.05 - 0.05 0.05 - 0.05
Low: 0.04 - 0.04 0.04 - 0.04
Close: 0.05 - 0.05 0.05 - 0.05

Company Description

PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiovascular diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients with uncontrolled major or life-threatening bleeding events or in patients requiring urgent or an invasive procedure. The company is also developing PB1046, a vasoactive intestinal peptide analogue for the treatment of pulmonary arterial hypertension; and PB6440 for the treatment of resistant hypertension. The company has a co-development agreement with SFJ Pharmaceuticals X, Ltd. to develop PB2452, a reversal agent for the antiplatelet drug ticagrelor. PhaseBio Pharmaceuticals, Inc. was incorporated in 2002 and is based in Malvern, Pennsylvania. On October 23, 2022, PhaseBio Pharmaceuticals, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.

Headline News

Wed, 01 Feb 2023
Sen. Cramer Reintroduces Bipartisan Bill to Create Affordable ... - Kevin Cramer

Wed, 01 Feb 2023
PHA: BERATING STAFF WILL NOT HELP – Eye Witness News - EyeWitness News

Mon, 30 Jan 2023
HUD Announces $800000 to Idaho Public Housing Agencies for ... - bigcountrynewsconnection.com

Mon, 30 Jan 2023
Biodegradable PHA Water Bottles Make Retail Debut - Packaging World

Mon, 23 Jan 2023
PHA Housing Voucher Lottery Opens - NBC 10 Philadelphia

Mon, 23 Jan 2023
Problems as PHA Housing Voucher Lottery Gets Underway - NBC 10 Philadelphia

Financial Analysis

Price to Book Value: Neutral
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Neutral
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Outperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Underperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 0 (M)
Shares Float 50 (M)
% Held by Insiders 3.441e+007 (%)
% Held by Institutions 6.7 (%)
Shares Short 1,470 (K)
Shares Short P.Month 0 (K)

Stock Financials

EPS -1.0226e+008
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin (%) 0
Operating Margin (%) -12
Return on Assets (ttm) 738.6
Return on Equity (ttm) -106.1
Qtrly Rev. Growth 818000
Gross Profit (p.s.) -34.15
Sales Per Share 0
EBITDA (p.s.) -3.18049e+007
Qtrly Earnings Growth -2.4
Operating Cash Flow 0 (M)
Levered Free Cash Flow -59 (M)

Stock Valuations

PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales 0
Price to Cash Flow -0.06

Stock Dividends

Dividend 0
Forward Dividend 2.07e+006
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.